How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

TD Cowen analyst Marc Frahm has maintained their bullish stance on INZY stock, giving a Buy rating on October 25. Marc Frahm has given his Buy ...

The growing demand for alopecia treatments is mainly driven by the rising global prevalence of alopecia, influenced by ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Shares of Sun Pharmaceutical Industries Ltd. 524715 inched down 0.31% to 1,803.25 Indian rupees Tuesday, on what proved to be ...